Table 2.

Time-varying multivariate Cox regression models for OS adjusted for age, sex, year of diagnosis, type of induction treatment and exposure to consolidation and maintenance treatment

Variable	Hazard ratio (95% CI)
Age at diagnosis (< 50 years, reference)
50–64 years	1.62 (1.23–2.13)
≥ 65 years	2.13 (1.55–2.93)
Sex (female, reference)
Male	0.90 (0.76–1.06)
Year of diagnosis (2005–2012, reference)
2013–2016	0.74 (0.59–0.93)
Type of induction regimen (IMiD-containing, reference)
Non-IMiD-containing	1.21 (0.93–1.58)
Exposure to consolidation therapy (no, reference)
Yes, < 1 year*	9.45 (5.25–17.00)
Yes, 1–2 years*	3.87 (2.11–7.08)
Yes, ≥ 2 years*	1.19 (0.6 5–2.18)
Exposure to maintenance therapy (no, reference)
Yes	0.80 (0.51–1.24)

TTNT, time to next treatment; OS, overall survival; CI, confidence interval; IMiD, immunomodulatory drug

*Refers to time from induction treatment initiation